Ovensa Inc.

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
Ovensa Inc. is a preclinical stage company developing a siRNA drug candidate silencing the overexpression of galectin-1 (Gal-1) in cancer.

Our preclinical data in recurrent glioblastoma, published in peer-reviewed journals, have shown that our siRNA (intranasal) combined with Temozolomide or checkpoint inhibitors had synergistic benefits and significantly improved median and long-term survival.

Gal-1 is a glycan-binding protein playing major roles in cancer by modulating different processes leading to metastasis, recurrence, enhanced cancer stem cell properties, resistance towards treatments (e.g. immunotherapy, chemotherapy, radiotherapy), and bad tumor prognosis.

Ovensa has entered into R&D collaborations with pharmaceutical companies for the use of its non-viral and non-lipidic TRIOZAN™ Nanomedicine Platform for targeted as well as mucosal and BBB-crossing drug delivery.

The company is looking for co-development partners or licensing its siRNA and DDS platform.
Company Type:
Company Website:
Company HQ State:
Ontario
Company HQ Country:
Canada
Year Founded:
2012
Main Therapeutic Focus:
Lead Product in Development:
siRNA/Galectin-1
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
President & CEO
Ovensa Inc.